Helping the World Be Well through Innovative Manufacturing

Slides:



Advertisements
Similar presentations
 AUTHOR- Musiba Baliruno Denis, B.pharm (MUST) SUPERVISORS ;  Prof. K.A.M. Kuria, PhD - Department of Pharmaceutics and Pharmacy Practice, University.
Advertisements

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Training Workshop on Pharmaceutical Development.
Statistical Approaches to Addressing the Requirements of the New FDA Process Validation Guidance for Small Molecules 1 Jason Marlin, MS/T Statistics, Eli.
The Gamlen Tablet Press (GTP) Michael Gamlen Gamlen Tableting Ltd.
By Timina Olive Kayaviri Supervisor : Dr. Amugune
Methods of tablet manufacturing
World Health Organization
Division of Pharmaceutical Analysis Research in support of the Critical Path Dimensions Ensuring Safety Demonstrating Medical Utility Industrialization.
Pharmtech Contract Services Offered by the Division of Pharmaceutical Technology.
Quality by Design (QbD) in Product Development
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
An Industry Perspective on the Potential for Emerging Process Analytical Technologies Norman Winskill Steve Hammond Pfizer Global Manufacturing Services.
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
LIFE SCIENCES Pharmaceutical Manufacturing Chemical & Biosciences Technology QA/QC in Pharmaceutical Industry Applied Biology & Chemistry.
AE 469/569 TERM PROJECT DEVELOPING CORRECTION FUNCTION FOR TEMPERATURE EFFECTS ON NIR SOYBEAN ANALYSIS Jacob Bolson Maureen Suryaatmadja Agricultural Engineering.
World Health Organization
Interchangeability and study design Drs. Jan Welink Training workshop: Training of BE assessors, Kiev, October 2009.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Xcellerex … speeding medicines to people … PAT for Biologics Ensuring Quality of Biologically Produced Drugs FDA Advisory Committee on Pharmaceutical Sciences.
Validation of Analytical Method
Total Quality Management System (TQMS) AstraZeneca Solid Dosage Facility, Plankstadt, Germany Ali Afnan AstraZeneca Pharmaceuticals Engineering Group Alderley.
FDA Regulatory Perspective on Continuous Manufacturing
Applications and benefits of PAT Steve Hammond Global Manufacturing Services Process Analytical Support Group Sandwich, UK.
Quality by Design Application of Pharmaceutical QbD for Enhancement of the Solubility and Dissolution of a Class II BCS Drug using Polymeric Surfactants.
Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.
Bob Chisholm TQMS STATISTICALLY BASED IN-PROCESS CONTROL WITH REAL TIME QUALITY ASSURANCE The AstraZeneca Total Quality Management Strategy R S Chisholm.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
Helping the World Be Well through Innovative Manufacturing
Applications of Analytical Chemistry in Pharmaceuticals Corey M. Chong 10Mar10.
Module 1, Part 3: Process validation Slide 1 of 22 © WHO – EDM – 12/2001 Validation Part 3: Process validation Supplementary Training Modules on Good Manufacturing.
1-7.The ICH Q8 “Minimal Approach” to Pharmaceutical Development
Quality control Lecture 1.
5 ft 3 V-blender w/ Spectrometer Brimrose 5030 wireless process spectrometer collection parameters: Spectra are collected once every rotation at 23 rpm.
DEVELOPMENT OF QUALITY BY DESIGN (QBD) GUIDANCE ELEMENTS ON DESIGN SPACE SPECIFICATIONS ACROSS SCALES WITH STABILITY CONSIDERATIONS Blending Benoit Igne,
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Implementation of ICH Q8, Q9, Q10.
Assessment of Interchangeable Multisource Medicines BCS-Biowaivers - Template Dr. Henrike Potthast Training workshop: Assessment of.
Critical Material Properties for Pharmaceutical Dosage Forms - Industry Perspective Tony Hlinak Abbott Laboratories North Chicago, IL.
Some Future Developments Brian Carlin, Ph.D FMC Chris Moreton, Ph.D FinnBrit Consulting IPEC-Americas FDA Seminar, October 21,
Satish Mallya January 20-22, |1 | 2-3. Pharmaceutical Development Satish Mallya Quality Workshop, Copenhagen May 18-21, 2014 May 18-21,2014.
FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm.
Blend Uniformity: Update Ajaz S. Hussain, Ph.D.. Background Issue: Assuring and documenting “adequacy of mixing” operations –PQRI’s Proposal Stratified.
Excipient Variability Sources, Importance and Potential Impact Chris Moreton, Ph.D Past Chair IPEC-Americas Partner – FinnBrit Consulting
Searching For Root Causes Under Pressure Using Data Visualization to Focus Investigations Dan Pilipauskas Pfizer Inc.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.
18.1 Introduction Powder metallurgy is a process by which fine powdered materials are blended, pressed into a desired shape, and then heated to bond.
Interchangeability and study design Drs. Jan Welink Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.
Quality control Lecture 1.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
QbD Technologies: Workshop for Risks Management Incorporating Risk Management for Technology Transfer.
Product & Process Working Group February 26, 2002.
EQUIPMENT and METHOD VALIDATION
TABLET GRANULATION TECHNIQUES.
Integration of Excipients into the Design of Experiments for Pharmaceutical Product and Design Space Development Chris Moreton, Ph.D. FinnBrit Consulting.
PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1.
HOLD-TIME STUDIES.
Process Capability and Capability Index
Enabling direct compaction at high drug loading via dry coating of APIs: Towards a predictive framework Presenter(s): Kuriakose T. Kunnath, NJIT Research.
,Branko Vranic1, Nada Tarek2 ,V. Frost 3, G. Betz1
Dr Dehghan M. H Professor in Pharmaceutics,
Strategies for Eliminating Interferences in Optical Emission Spectroscopy Best practices to optimize your method and correct for interferences to produce.
Quality control Lecture 1.
Lab -7- Capsules.
Lab -7- Capsules.
Quality by Design.
ANALYTICAL METHOD VALIDATION
Tablets Lecturer: dr. Asmaa abdelaziz Mohamed Faculty of pharamcay
Quality control Lecture 1.
RingCap Technology Mrs. Maria Saifee Associate Professor,
Presentation transcript:

Helping the World Be Well through Innovative Manufacturing Process Analytical Technology (PAT) for Blend Uniformity Challenges and Lessons Learned Jim Donato1, K. Ganeshwar Prasad1, Fernando Rodriguez-Ares2, Shaira Davila1, Brandye Smith-Goettler3, Manoharan Ramasamy3, Peter Brush3 1 Pharmaceutical Commercialization Technology, MSD Intl GmbH (PR Branch), Las Piedras, PR 2 Integrated Project Team, MSD Intl GmbH (PR Branch), Las Piedras, PR 3 ACDS-PAT, Merck, West Point Helping the World Be Well through Innovative Manufacturing

Drug Product Manufacture API Assay by PAT Blend Uniformity by PAT Blend Uniformity by PAT

Why Blend The uniformity of the blend is critical in the establishment of the uniformity of the dosage units Powder blending of active/excipient is an important and common unit operation for solid oral dosage systems Direct compression, roller compaction, wet granulation, hot melt extrusion For most formulations, it is important to ensure the uniformity of the excipients as well as the API Inhomogeneity may lead to: Poor flow, sticking/picking/capping/delamination, improper disintegration and/or dissolution, sub- and/or super- potent tablets

Disadvantages of Traditional Blend Sampling Conventional procedure: Blend Uniformity samples are collected using a powder thief and analyzed using HPLC, UV-Vis, LIBS or other off-line laboratory technique Labor intensive for both the operator and lab personnel (IBC’s moved to different areas to sample/PPE, typically 4 hrs) Difficult to reproduce sampling technique (and thus blend result) Blender must be stopped to sample blend Long turn-around times for sample analysis Typically not performed once validated in production Potential for exposure of operators to high potency API’s Act of sampling, in itself, may produce sample non-uniformity If anyone in the room has ever had to thief sample an 1800 L bin – they know this is hard work The results - It is formulation – product – blend dependent

NIR as Alternative BU Method Real-time monitoring Monitor API, excipients and lubricant Non-invasive Minimizes inter-operator variability and sample thief failures Collects blend sample at each rotation thus providing process understanding Used for IBC (bin) blenders from 5L (dev) to 1800L+ commercial scale Reduces sample analysis burden on laboratory Improved safety profile as product exposure eliminated

NIR BU Method Considerations-Instrumentation # of Sample/Reference scans 4/128 Effective sample size 200-800mg* Analyzer/bin interface Sapphire window lid with clamp Spectral resolution 8cm-1 Spectral coverage range 5550-7400cm-1 Data acquisition trigger Internal at 150-160° Spectral collection time 1.5s Instrumentation Performance attributes Functional attributes Data collection parameters Spectroscopy API, placebo excipient Got specificity? Sampling interface Non-contact Sapphire window Tri-clamp API Placebo Raw Absorbance spectra

NIR BU Method Considerations – Blend Metrics Qualitative Algorithm Mathematical transformation to connect spectral variability to blend endpoint – moving block average of spectral variation – either in terms of SD or %RSD With specificity Peak Maxima/Minima Max or Min in range Peak area, peak average, root mean square Without specificity Average spectrum Standard deviation spectrum PCA other Connect Spectral Variability to Blend Endpoint

Blend Control Strategy - PAT end-point control via spectral %RSD Risk Mitigated Variations in the lubrication process impact tablet hardness/tensile strength and in turn disintegration and dissolution due to over-lubrication of the blend The blend NIRS dataset compiled with data from: Two manufacturing sites Four scales (150L, 300L, 600L and 800L) Two different spectrometers Fill volumes (27 – 85%)

Scale Up Challenge Scale up: 1400L IBC Different Pivot Point Axis of rotation Pre-blending Blending Scale up: 1400L IBC Different Pivot Point Axis of Rotation Shifted up Bi-directional rotation API blend batches as part of Process Validation All batches pass BU specifications Batch #6 stands out as atypical

NIR Model and Batch Variation As per thief sampling and NIR protocol, all batches complied with BU specifications Without NIR, and using only standard BU protocol, no further action needed With NIR, blend endpoint for Batch #6 was ~2x revolutions compared to others Without the NIR blend profile, process variability is not visible Initiated investigation into why blend is different: Possible causes include: raw material/API variability (particle size, density, fill volume), equipment failures (speed, directional change, blend lid), NIR instrument/sampling/algorithm concerns

Conclusions NIR for online monitoring of BU provides several advantages over powder thief sampling Multiple components can be monitored simultaneously API, lubricant, critical excipient Full blend profiles are obtained rather than single point of data Slug thief sampling is preferred method of sampling for validation of NIR method NIR was used to identify several possible processing issues Sample thief problems and BU failures Powder blend/lubricant sticking during large scale blending Overall endpoint variability in commercial scale blending operations Identified an Out-of-Trend blend profile during process validation

Acknowledgements West Point Las Piedras Las Piedras SLT Mike Gentzler Steve Conway Andre Hermans Jessica Miller Colleen Neu Brandon Ricart Las Piedras Glenda Rodriguez Luz Rodriguez Ana Diaz …and others Las Piedras SLT Patrick Breen Humberto Diaz Luis O. Garcia Andrew Wirths